

# FINANCIAL TEAR SHEET

## Corporate Profile

KindredBio is a biotechnology company that develops medicines for pets. We believe that our animal family members deserve the same great medicines that human family members enjoy.

### **The Approach**

We identify drugs, biologics, and targets that have been validated in humans and develop animal versions to treat and cure pets. We seek to leverage the investments that have been made in human pharmaceutical R&D to develop therapies for pets with lower risk, lower cost, and shorter time-to-market, compared to human drug development.

### **The Opportunity**

We believe KindredBio can deliver superior returns to investors because while the market sizes for pet drugs are about 10-fold smaller compared to human market sizes, the cost of development is 100-fold less.

### **World Class Team**

KindredBio is one of the first pet biotechs in the world, and we have a world-class team, including the former Director of FDA's Center for Veterinary Medicine and the former Head of Biotherapeutics Clinical Research at Genentech. Because of the team, and because we do not outsource our clinical studies, we can move at a very rapid pace. We anticipate 2 launches in less than 2 years.

In addition, in the technically demanding area of biologics, KindredBio also has one of the most experienced teams in the pharmaceutical industry, with experts drawn from companies like Genentech and Amgen. We also have access to some of the most cutting-edge antibody technologies.

### **Contact Us**

To contact investor relations, or to request an investor packet, please call 650.701.7904 or email [IR@kindredbio.com](mailto:IR@kindredbio.com).

## Stock Information

### KIN (Common Stock)

Exchange	NASDAQ CM (US Dollar)
Price	<b>\$8.90</b>
Change (%)	▲ 0.15 (1.71%)
Volume	120,086
52 Week Low	\$5.00
Market Cap	\$250,610,935
Rolling EPS	-1.17
PE Ratio	0
Shares Outstanding	28,158,532

Data as of 01/19/18 4:00 p.m. ET



## Recent Press Releases & Upcoming Events

December 21, 2017

There are currently no events scheduled.

[KindredBio Announces Submission of European Medicines Agency Filing for Mirataz™](#)

December 4, 2017

[KindredBio Announces Positive Results from Pivotal Study of Zimeta Oral for Fever in Horses](#)

November 7, 2017

[Kindred Biosciences Announces Third Quarter 2017 Financial Results](#)

## SEC Filings

Filing Date	Form
01/17/18	<a href="#">S-3</a>
01/04/18	<a href="#">4</a>
12/08/17	<a href="#">CTORDER</a>
11/07/17	<a href="#">10-Q</a>

## Corporate Governance